KEYNOTE-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, David Carbone, MD, PhD, of Ohio State University, Athens, OH, discusses the KEYNOTE-042 trial (NCT02220894), w... Author: VJOncology Added: 07/27/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts